Back to News
Market Impact: 0.3

Validea Detailed Fundamental Analysis

OSCRNDAQ
Company FundamentalsAnalyst InsightsCorporate EarningsInsider TransactionsHealthcare & Biotech
Validea Detailed Fundamental Analysis

Validea's guru fundamental report rates Oscar Health Inc (OSCR), a mid-cap growth insurer, at 55% using the Motley Fool Small-Cap Growth Investor model, which falls below the 80% threshold typically indicating investor interest. The analysis reveals significant fundamental weaknesses in profit margin, sales and EPS growth, cash flow from operations, and its P/E to growth ratio, despite exhibiting strengths in relative price performance and cash position.

Analysis

Oscar Health Inc. (OSCR) scores a notably low 55% on Validea's Motley Fool Small-Cap Growth model, falling significantly short of the 80% threshold that typically indicates strategic interest. The analysis reveals a significant disconnect between the stock's price behavior and its underlying business fundamentals. While OSCR passes criteria for relative price strength, profit margin consistency, and balance sheet health regarding cash and accounts receivable, it fails on several critical performance and valuation metrics. Most concerning are the failures in core areas such as profit margin, sales growth, and year-over-year EPS growth. Furthermore, the company fails to generate positive cash flow from operations and its valuation appears stretched, as indicated by a failing score on the P/E to Growth ("The Fool Ratio") test. The lack of insider holdings and low daily dollar volume compound these risks, painting a picture of a stock with positive price momentum that is not supported by fundamental operational strength or valuation.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

moderately negative

Sentiment Score

-0.50

Ticker Sentiment

NDAQ0.00
OSCR-0.50

Key Decisions for Investors

  • Investors should be cautious as the stock's strong relative price performance appears disconnected from its weak underlying fundamentals, particularly the failing grades on profit margin, sales growth, and cash flow from operations.
  • Given the failure on the P/E-to-Growth valuation metric, the stock may be overvalued relative to its growth prospects, warranting a re-evaluation of its current price.
  • The combination of low insider holdings and low daily trading volume suggests potential risks related to management conviction and liquidity, which should be monitored closely before initiating or adding to a position.